Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with HF with reduced ejection fraction, and, in the case of empagliflozin, in HF with preserved ejection fract...
Alternative Titles
Full title
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2709317582
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2709317582
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2022.05.010
